- Home
- NVGS vs NRIX Comparison
NVGS vs NRIX Comparison
Compare NVGS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- NRIX
- Stock Information
- Founded
- NVGS 1997
- NRIX 2009
- Country
- NVGS United Kingdom
- NRIX United States
- Employees
- NVGS N/A
- NRIX N/A
- Industry
- NVGS Marine Transportation
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- NRIX Health Care
- Exchange
- NVGS Nasdaq
- NRIX Nasdaq
- Market Cap
- NVGS 957.8M
- NRIX 1.1B
- IPO Year
- NVGS N/A
- NRIX 2020
- Fundamental
- Price
- NVGS $10.76
- NRIX $9.74
- Analyst Decision
- NVGS Strong Buy
- NRIX Strong Buy
- Analyst Count
- NVGS 3
- NRIX 17
- Target Price
- NVGS $22.00
- NRIX $30.82
- AVG Volume (30 Days)
- NVGS 271.4K
- NRIX 1.0M
- Earning Date
- NVGS 05-14-2025
- NRIX 04-14-2025
- Dividend Yield
- NVGS 1.64%
- NRIX N/A
- EPS Growth
- NVGS 8.18
- NRIX N/A
- EPS
- NVGS 1.19
- NRIX N/A
- Revenue
- NVGS $566,679,000.00
- NRIX $54,549,000.00
- Revenue This Year
- NVGS $5.93
- NRIX N/A
- Revenue Next Year
- NVGS N/A
- NRIX $3.20
- P/E Ratio
- NVGS $11.11
- NRIX N/A
- Revenue Growth
- NVGS 2.90
- NRIX N/A
- 52 Week Low
- NVGS $12.23
- NRIX $10.21
- 52 Week High
- NVGS $18.18
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- NVGS 11.71
- NRIX 27.01
- Support Level
- NVGS $13.15
- NRIX $10.21
- Resistance Level
- NVGS $14.47
- NRIX $13.10
- Average True Range (ATR)
- NVGS 0.44
- NRIX 0.77
- MACD
- NVGS -0.18
- NRIX -0.16
- Stochastic Oscillator
- NVGS 2.91
- NRIX 3.74
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.